Jian-Dong Li Selected Research

vinpocetine

1/2020	Vinpocetine Suppresses Streptococcus pneumoniae-Induced Inflammation via Inhibition of ERK1 by CYLD.
1/2018	An update on vinpocetine: New discoveries and clinical implications.
4/2017	Vinpocetine Attenuates Pathological Cardiac Remodeling by Inhibiting Cardiac Hypertrophy and Fibrosis.
6/2015	Vinpocetine inhibits Streptococcus pneumoniae-induced upregulation of mucin MUC5AC expression via induction of MKP-1 phosphatase in the pathogenesis of otitis media.
5/2013	Vinpocetine attenuates lipid accumulation and atherosclerosis formation.
11/2012	Vinpocetine suppresses pathological vascular remodeling by inhibiting vascular smooth muscle cell proliferation and migration.
5/2010	Vinpocetine inhibits NF-kappaB-dependent inflammation via an IKK-dependent but PDE-independent mechanism.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jian-Dong Li Research Topics

Disease

28	Inflammation (Inflammations) 01/2021 - 03/2004
18	Infections 09/2016 - 01/2002
13	Otitis Media 03/2020 - 05/2002
10	Chronic Obstructive Pulmonary Disease (COPD) 11/2018 - 01/2002
9	Neoplasms (Cancer) 01/2021 - 08/2004
8	Bacterial Infections (Bacterial Infection) 11/2015 - 12/2002
6	Pneumonia (Pneumonitis) 11/2015 - 01/2008
5	Cystic Fibrosis (Mucoviscidosis) 01/2019 - 04/2006
4	Vascular Remodeling 04/2022 - 12/2010
4	Carcinogenesis 04/2022 - 08/2004
4	Fibrosis (Cirrhosis) 04/2021 - 04/2012
4	Cognitive Dysfunction 04/2017 - 05/2010
3	Hypertension (High Blood Pressure) 01/2020 - 03/2015
3	Hypertrophy 11/2018 - 11/2009
3	Atherosclerosis 01/2018 - 11/2012
3	Communicable Diseases (Infectious Diseases) 06/2013 - 07/2003
3	Myocardial Infarction 05/2013 - 05/2009
3	Respiratory Tract Diseases (Respiratory Tract Disease) 12/2008 - 01/2008
2	Hyperbilirubinemia 12/2021 - 01/2021
2	Pulmonary Fibrosis (Fibrosing Alveolitis) 04/2021 - 01/2015
2	Otitis Media with Effusion 03/2020 - 01/2002
2	Human Influenza (Influenza) 03/2020 - 01/2018
2	Obstructive Lung Diseases (Obstructive Lung Disease) 01/2020 - 12/2016
2	Stroke (Strokes) 01/2018 - 05/2013
2	Cerebrovascular Disorders (Cerebrovascular Occlusion) 01/2018 - 05/2010
2	Cardiomegaly (Heart Hypertrophy) 04/2017 - 11/2009
2	Lung Injury 10/2016 - 04/2012
2	Acute Lung Injury 10/2016 - 10/2011
2	Sepsis (Septicemia) 11/2015 - 10/2011
2	ST Elevation Myocardial Infarction 12/2010 - 05/2009
2	Conductive Hearing Loss 05/2009 - 01/2002
2	Asthma (Bronchial Asthma) 02/2008 - 01/2008
2	Colonic Neoplasms (Colon Cancer) 01/2005 - 09/2002
1	Insulin Resistance 04/2022
1	Nervous System Diseases (Neurological Disorders) 04/2022
1	Neonatal Hyperbilirubinemia 12/2021
1	Glucosephosphate Dehydrogenase Deficiency 12/2021
1	Peritonitis 12/2021
1	Diabetic Nephropathies (Diabetic Nephropathy) 01/2021
1	Type 2 Diabetes Mellitus (MODY) 01/2021
1	Chronic Renal Insufficiency 01/2021
1	Hereditary Nephritis (Alport Syndrome) 01/2021
1	Proteinuria 01/2021
1	Sclerosis 01/2021

Drug/Important Bio-Agent (IBA)

14	MucinsIBA 01/2020 - 01/2002
11	NF-kappa B (NF-kB)IBA 03/2012 - 08/2004
8	CytokinesIBA 01/2019 - 09/2002
7	vinpocetineIBA 01/2020 - 05/2010
7	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2020 - 03/2004
6	Deubiquitinating EnzymesIBA 01/2016 - 03/2012
5	AlkaloidsIBA 01/2018 - 05/2010
5	VincamineIBA 01/2018 - 05/2010
5	GlucocorticoidsIBA 01/2015 - 05/2002
4	Transcription Factors (Transcription Factor)IBA 01/2011 - 08/2004
4	Transforming Growth Factor beta (TGF-beta)IBA 01/2009 - 11/2002
3	CholesterolIBA 04/2022 - 05/2013
3	Angiotensin IIIBA 01/2020 - 11/2009
3	Phosphoric Diester Hydrolases (Phosphodiesterases)IBA 04/2017 - 11/2009
3	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2015 - 07/2003
3	Anti-Bacterial Agents (Antibiotics)IBA 12/2014 - 01/2002
3	Antiviral Agents (Antivirals)IBA 06/2011 - 07/2007
3	TNF Receptor-Associated Factor 6 (TRAF6)IBA 10/2007 - 08/2004
2	BilirubinIBA 12/2021 - 01/2021
2	VaccinesIBA 03/2020 - 01/2003
2	p38 Mitogen-Activated Protein KinasesIBA 01/2020 - 01/2010
2	ChemokinesIBA 01/2019 - 03/2004
2	Type 4 Cyclic Nucleotide PhosphodiesterasesIBA 11/2018 - 04/2015
2	RoflumilastIBA 11/2018 - 04/2015
2	Cyclic NucleotidesIBA 04/2017 - 11/2009
2	Pharmaceutical PreparationsIBA 01/2017 - 11/2016
2	CurcuminIBA 01/2017 - 01/2016
2	Dual Specificity Phosphatase 1IBA 01/2017 - 06/2015
2	ResveratrolIBA 09/2016 - 04/2011
2	Isoproterenol (Isoprenaline)FDA LinkGeneric 01/2016 - 11/2009
2	Glycoproteins (Glycoprotein)IBA 10/2014 - 06/2008
2	Deubiquitinating Enzyme CYLDIBA 02/2014 - 08/2007
2	Interleukin-8 (Interleukin 8)IBA 01/2014 - 01/2010
2	Proteins (Proteins, Gene)FDA Link 04/2012 - 06/2008
2	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 03/2012 - 09/2002
2	Blood Glucose (Blood Sugar)IBA 12/2010 - 05/2009
2	Glucose (Dextrose)FDA LinkGeneric 12/2010 - 05/2009
2	Transcription Factor AP-1 (Transcription Factor AP 1)IBA 01/2010 - 10/2008
2	beta-DefensinsIBA 05/2004 - 06/2002
1	DolicholsIBA 04/2022
1	EnzymesIBA 12/2021
1	Glucosephosphate Dehydrogenase (Glucose 6 Phosphate Dehydrogenase)IBA 12/2021
1	Hematoxylin (Haematoxylon)IBA 04/2021
1	Bleomycin (Blenoxane)FDA LinkGeneric 04/2021
1	Eosine Yellowish-(YS) (Eosin)IBA 04/2021
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2021
1	Losartan (Cozaar)FDA LinkGeneric 01/2021
1	Metformin (Glucophage)FDA LinkGeneric 01/2021
1	MicroRNAs (MicroRNA)IBA 03/2020
1	InflammasomesIBA 03/2020
1	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 01/2020
1	Glucagon-Like Peptide 1 (GLP 1)IBA 01/2020
1	Glucagon-Like Peptide-1 ReceptorIBA 01/2020
1	Glucagon-Like Peptide-1 Receptor AgonistsIBA 01/2020

Therapy/Procedure

3	Therapeutics 08/2014 - 12/2008
1	Peritoneal Dialysis 12/2021